Jafron Biomedical Co.,Ltd. (SHE: 300529)

Jafron Biomedical Co.,Ltd. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	720.88	2,810	2,559	2,319	1,575	1,272
Trading Asset Securities	1,993	-	-	150.01	-	-
Cash & Short-Term Investments	2,714	2,810	2,559	2,469	1,575	1,272
Cash Growth	0.38%	9.83%	3.62%	56.79%	23.85%	17.67%
Accounts Receivable	199.14	81.21	239.64	308.06	215.8	160.66
Other Receivables	18.67	6.51	6.85	6.32	9.78	9.16
Receivables	217.81	87.72	246.49	314.37	225.58	169.82
Inventory	312.56	385	349.13	196.55	120.67	92.31
Prepaid Expenses	-	0.32	14.55	-	-	-
Other Current Assets	47.61	28.5	124.32	75.27	65.31	25.88
Total Current Assets	3,292	3,312	3,293	3,056	1,987	1,560
Property, Plant & Equipment	1,807	1,771	1,672	1,272	905.51	639.63
Long-Term Investments	116.13	116.13	69.45	111.2	98.99	100.79
Goodwill	12.21	12.21	37.81	44.07	44.07	44.07
Other Intangible Assets	98.51	100.37	100.43	101.31	89.89	48.05
Long-Term Deferred Tax Assets	32.52	30.35	36.49	26.54	12.97	10.07
Long-Term Deferred Charges	87.81	94.87	59	35.95	20.42	14.82
Other Long-Term Assets	147.01	107.03	148.22	162.91	58.22	77.49
Total Assets	5,593	5,543	5,417	4,810	3,217	2,495
Accounts Payable	130.13	135.62	128.52	60.76	50.22	32.83
Accrued Expenses	51.93	158.21	157.48	192.98	139.79	98
Short-Term Debt	242.93	261.83	317.09	-	-	-
Current Portion of Long-Term Debt	96.28	16.79	-	-	-	-
Current Portion of Leases	-	3.83	4.73	3.17	-	-
Current Income Taxes Payable	125.82	30.52	2.55	23.19	52.14	23.63
Current Unearned Revenue	12.23	37.57	42.3	20.65	26.95	7.97
Other Current Liabilities	213.54	185.03	64.52	85.51	61.73	100.2
Total Current Liabilities	872.87	829.42	717.18	386.26	330.82	262.63
Long-Term Debt	1,277	1,381	936.78	897.37	-	-
Long-Term Leases	1.05	11.35	17.34	17.01	-	-
Long-Term Unearned Revenue	134.95	151.78	151.66	125.08	51.7	60.68
Long-Term Deferred Tax Liabilities	13.67	16.78	3.12	0.73	0.54	0.81
Total Liabilities	2,300	2,390	1,826	1,426	383.06	324.13
Common Stock	798.61	807.56	807.71	805.5	799.11	418.66
Additional Paid-In Capital	226.75	694.14	678.04	618	347.9	606.05
Retained Earnings	2,890	2,408	2,507	2,336	1,670	1,173
Treasury Stock	-744.35	-880.63	-509.69	-523.8	-13.52	-59.65
Comprehensive Income & Other	118.63	118.63	91.7	123.14	3.08	4.62
Total Common Equity	3,289	3,147	3,574	3,359	2,807	2,142
Minority Interest	3.96	5.4	16.17	24.79	26.82	28.06
Shareholders' Equity	3,293	3,153	3,590	3,384	2,834	2,171
Total Liabilities & Equity	5,593	5,543	5,417	4,810	3,217	2,495
Total Debt	1,618	1,675	1,276	917.55	-	-
Net Cash (Debt)	1,096	1,135	1,283	1,552	1,575	1,272
Net Cash Growth	13.60%	-11.49%	-17.34%	-1.47%	23.85%	17.67%
Net Cash Per Share	1.38	1.43	1.62	1.93	1.94	1.60
Filing Date Shares Outstanding	774.36	774.47	798.87	815.46	798.53	795.46
Total Common Shares Outstanding	774.36	774.47	798.86	815.46	799.11	795.46
Working Capital	2,419	2,482	2,576	2,669	1,656	1,297
Book Value Per Share	4.25	4.06	4.47	4.12	3.51	2.69
Tangible Book Value	3,179	3,035	3,436	3,213	2,673	2,050
Tangible Book Value Per Share	4.10	3.92	4.30	3.94	3.34	2.58
Buildings	-	1,260	890.61	812.74	555.36	473.23
Machinery	-	678.23	514.6	304.98	212.71	167.51
Construction In Progress	-	122.43	473.99	301.15	262.68	91.74

Source: S&P Capital IQ. Standard template. Financial Sources.